NYSE:CNC - Centene Stock Price, Forecast & News

Centene trades on the New York Stock Exchange (NYSE) under the ticker symbol "CNC."

Centene shares split on Wednesday, February 6th 2019. The 2-1 split was announced on Tuesday, February 5th 2019. The newly created shares were issued to shareholders after the market closes on Tuesday, February 5th 2019. An investor that had 100 shares of Centene stock prior to the split would have 200 shares after the split.

Centene Corp (NYSE:CNC) posted its quarterly earnings data on Tuesday, October, 22nd. The company reported $0.96 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $0.95 by $0.01. The company had revenue of $18.98 billion for the quarter, compared to analyst estimates of $18.39 billion. Centene had a return on equity of 15.54% and a net margin of 1.87%. The company's revenue was up 17.3% on a year-over-year basis. During the same quarter last year, the firm posted $1.79 earnings per share. View Centene's Earnings History.

Centene is scheduled to release their next quarterly earnings announcement on Tuesday, February 4th 2020. View Earnings Estimates for Centene.

Centene updated its FY20 earnings guidance on Thursday, December, 12th. The company provided earnings per share (EPS) guidance of $4.64 to $4.84 for the period, compared to the Thomson Reuters consensus EPS estimate of $4.84. The company issued revenue guidance of $78.6-79.4 billion, compared to the consensus revenue estimate of $79.65 billion.

12 equities research analysts have issued 12-month price targets for Centene's shares. Their forecasts range from $57.00 to $83.00. On average, they anticipate Centene's share price to reach $72.05 in the next twelve months. This suggests a possible upside of 25.3% from the stock's current price. View Analyst Price Targets for Centene.

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Centene in the last year. There are currently 2 hold ratings and 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Centene.

News coverage about CNC stock has trended somewhat positive this week, according to InfoTrie. The research firm scores the sentiment of news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Centene earned a coverage optimism score of 1.7 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View News Stories for Centene.

Centene saw a increase in short interest in November. As of November 15th, there was short interest totalling 43,160,000 shares, an increase of 5.8% from the October 31st total of 40,810,000 shares. Based on an average trading volume of 4,990,000 shares, the short-interest ratio is presently 8.6 days. Approximately 10.8% of the shares of the stock are short sold. View Centene's Current Options Chain.

Some companies that are related to Centene include UnitedHealth Group (UNH), Cigna (CI), Anthem (ANTM), Humana (HUM), WellCare Health Plans (WCG), Molina Healthcare (MOH), Magellan Health (MGLN) and Triple-S Management (GTS).

Based on aggregate information from My MarketBeat watchlists, some companies that other Centene investors own include NVIDIA (NVDA), Alibaba Group (BABA), UnitedHealth Group (UNH), Visa (V), Micron Technology (MU), Netflix (NFLX), Home Depot (HD), Adobe (ADBE), CVS Health (CVS) and Mastercard (MA).

Centene's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include State Street Corp (4.00%), Maverick Capital Ltd. (1.75%), Boston Partners (1.05%), Third Point LLC (0.58%), Voya Investment Management LLC (0.45%) and Sumitomo Mitsui Trust Holdings Inc. (0.42%). Company insiders that own Centene stock include Brandy Burkhalter, Christopher D Bowers, Jeffrey A Schwaneke, Jesse N Hunter, Jessica L Blume, Keith H Williamson, Mark J Brooks, Michael F Neidorff, Robert K Ditmore and Stephen Wallace. View Institutional Ownership Trends for Centene.

CNC stock was sold by a variety of institutional investors in the last quarter, including State of New Jersey Common Pension Fund D, Scout Investments Inc., Carillon Tower Advisers Inc., Boston Partners, TimesSquare Capital Management LLC, Parametric Portfolio Associates LLC, Russell Investments Group Ltd. and California Public Employees Retirement System. Company insiders that have sold Centene company stock in the last year include Christopher D Bowers, Jeffrey A Schwaneke, Jesse N Hunter, Mark J Brooks, Michael F Neidorff and Robert K Ditmore. View Insider Buying and Selling for Centene.

CNC stock was purchased by a variety of institutional investors in the last quarter, including Maverick Capital Ltd., Man Group plc, Vantage Investment Partners LLC, Cambiar Investors LLC, Mackay Shields LLC, Voloridge Investment Management LLC, Retirement Systems of Alabama and Coronation Fund Managers Ltd.. Company insiders that have bought Centene stock in the last two years include Jessica L Blume and Stephen Wallace. View Insider Buying and Selling for Centene.

Shares of CNC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of CNC stock can currently be purchased for approximately $57.52.

Centene has a market capitalization of $23.80 billion and generates $60.12 billion in revenue each year. The company earns $900 million in net income (profit) each year or $3.54 on an earnings per share basis. Centene employs 47,300 workers across the globe.View Additional Information About Centene.

The official website for Centene is http://www.centene.com/.

Centene's mailing address is 7700 FORSYTH BOULEVARD, ST LOUIS MO, 63105. The company can be reached via phone at 314-725-4477 or via email at [email protected]